Piper Jaffray Reiterates Neutral and PT of Idexx Laboratories

Piper Jaffray reiterated its Neutral rating on Idexx Laboratories IDXX. At the same time, the rating agency left its price target on the company's stock unchanged at $78. On Friday, IDXX lost 1.7% of its value to finish the week at $74.45.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: ReiterationAnalyst RatingsHealth CareHealth Care EquipmentPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!